Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivatives by James, Edward et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/98504/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
James, Edward, Pertusati, Fabrizio, Brancale, Andrea and McGuigan, Christopher 2017. Kinase-
independent phosphoramidate S1P1 receptor agonist benzyl ether derivatives. Biorganic and
Medicinal Chemistry Letters 27 (6) , pp. 1371-1378. 10.1016/j.bmcl.2017.02.011 file 
Publishers page: http://dx.doi.org/10.1016/j.bmcl.2017.02.011
<http://dx.doi.org/10.1016/j.bmcl.2017.02.011>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Kinase-Independent Phosphoramidate S1P1 Receptor Agonist Benzyl Ether Derivatives 
 
Edward James*, Fabrizio Pertusati, Andrea Brancale and Chris McGuigan 
 
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, 
Cardiff, CF10 3NB, UK 
*Corresponding author.  Email address: edward.james.correspondence@hotmail.com 
 
Key words 
 
S1P1 receptor agonist, Benzyl ether derivative, Phosphoramidate, ProTide, Sphingosine kinase, 
Enzymatic processing 
 
 
Abstract 
 
Previously published S1P receptor modulator benzyl ether derivatives have shown potential as 
being viable therapeutics for the treatment of neurodegenerative diseases, however, two of the 
most S1P1-selective compounds are reported as being poorly phosphorylated by kinases in vivo. 
Phosphoramidates of BED compounds (2a, 2b) were synthesised with the aim of producing kinase-
independent S1P receptor modulators. Carboxypeptidase, human serum and cell lysate processing 
experiments were conducted. ProTide BED analogues were found to have an acceptable level of 
stability in acidic and basic conditions and in vitro metabolic processing experiments showed that 
they are processed to the desired pharmacologically active monophosphate. The research 
describes the development of an entirely novel family of therapeutic agents. 
 
  
 
 
 
Sphingosine 1-phosphate (S1P) receptor modulators have been the subject of significant interest 
since the emergence of FTY720 (fingolimod, 1) as the world’s first FDA approved oral treatment 
for relapsing-remitting multiple sclerosis.1 S1P receptors are G protein-coupled receptors 
expressed in a variety of tissues and cover a broad range of different physiological functions 
including lymphocyte trafficking.2 Sphingosine is phosphorylated by sphingosine kinase to form 
the natural S1P receptor ligand sphingosine 1-phosphate.3 1 is phosphorylated similarly to 
fingolimod-phosphate (1-P) by sphingosine kinase.4 Agonism of the S1P1 receptor by 1-P induces 
sequestration of T-cells in the lymphocytes and thereby reduces the infiltration of lymphocytes 
into the central nervous system.5  
 
Achieving a high level of S1P1 selectivity for novel S1P receptor modulators has been the focus for 
a number of academic and industrial groups.6,7,8 1-P is reported to have comparable affinities to 
the S1P1 and S1P3 receptors (Table 1) and it is the agonism of the S1P3 receptor which has been attributed to some of FTY720’s unwanted side effects such as bradycardia and hypertension.1,2  
Benzyl ether derivatives 2a-P and 2b-P previously published by Tsuji et al were reported to have 
far greater S1P1 selectivity than 1-P with EC50 values for S1P3 significantly higher than for S1P1 
(Table 1).9 However, the analogues reported as being the most S1P1-selective such as 2b-P were 
found to be poorly phosphorylated by kinases in rat blood and were not progressed. 
  
Figure 1. Structures of FTY720 (Fingolimod, 1), benzyl ether derivatives (2a and 2b) and their 
phosphates (1-P, 2a-P and 2b-P).9 
 
Phosphoramidate (ProTide) technology is a phosphate delivery technology which is typically 
applied to nucleosides.10,11 Often the rate-limiting step of nucleoside activation is phosphorylation 
by kinases and therefore phosphoramidate technology is applied to nucleosides to bypass the rate-
limiting step.12 ProTide technology masks the charges of the phosphate motif and increases the 
lipophilicity of the nucleoside and aids passive diffusion of the compound across the cell 
membrane.13 Once inside the cell ProTide nucleosides have been found to be processed to the 
monophosphate by enzymes such as cathepsin A and Hint.13,14,15 
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Table 1. In vitro agonist-evoked GTPγS binding of phosphates of FTY720 (1-P) and benzyl ether 
derivatives 2a-P and 2b-P to human S1P1 snd S1P3 as reported by Tsuji et al.9 
 
Compound γGTP EC50 (nM) Selectivity 
 S1P1 S1P3 (S1P3 / S1P1) 
1-P 7.0 2.0 0.29 
2a-P 7.0 200 29 
2b-P 6.5 >20,000 >3077 
 
It was decided that the application of phosphoramidate technology to previously published benzyl 
ether derivatives9 might be an effective way of improving the efficacy of the parent compounds 
particularly in kinase deficient environments. The synthesis of benzyl ether derivatives 2a and 2b 
was attempted and successfully achieved. The aim was then to synthesise phosphoramidate 
analogues and determine using in vitro testing whether ProTide BED analogues can be processed 
to the pharmacologically active monophosphate. 
 
The synthesis of benzyl ether derivatives 2a and 2b was successfully achieved by carefully 
following the reported experimental procedures in the original paper9 and a number of other 
sources.16-22 Some minor modifications to the synthetic procedure previously reported by Tsuji et 
al were made. The most significant alterations to the reported synthetic procedure were made to 
the synthesis of 2b.  The synthesis of the compounds in the early stages of the total synthesis 
(compounds 4 – 7) were developed using experimental procedures from a number of sources and 
repeated experimentation was required in order to synthesise the desired compounds with 
acceptable yields. 
 
An amalgamation of synthetic procedures found in three papers9,16,17 was eventually developed to 
yield 4 in acceptable yields (>80%). The synthesis of the 5 was eventually tuned after a similar 
process of experimentation and a combination of different experimental procedures from different 
papers.9,17,18 Notably a Dean Stark trap was used for the synthesis of 4 and 5. The synthesis of 6 
also underwent a number of variations and the final procedure was also devised from a 
combination of procedures from different papers9,19,20 and fine tuning of the experimental 
technique. An unusual quirk of the synthesis, as shown in scheme 1, is that if the reaction is done 
at -78 °C the whole mixture congeals and forms a hard solid but if the mixture is kept at -74 °C the 
reaction is effective. At temperatures much warmer than -74 °C the yield is compromised. 
Achieving this delicate balance in temperature was accomplished by simply conducting the 
reaction in a dry ice bath with no added acetone. Synthesis of 7 underwent fewer variations than 
the preceding three compounds. The synthesis was developed principally using two papers.9,20 The 
key modifications made to the original procedure devised were an increase in temperature to 45 
°C from room temperature, addition of toluene to the reaction mixture and the use of LiCl and KBH4 
as opposed to the more moisture sensitive LiBH4.  
 
Once achieving satisfactory yields of 4, 5, 6, and 7 was attained the rest of the synthetic process for 
the synthesis of 2a was more straightforward to accomplish as the later stages are detailed in the 
experimental section of the lead paper.9 The final 2a compound synthesised was analysed using 
polarimetry to measure the optical rotation giving an optical rotation value of [Ƚ] = 25.12  ([Ƚ]D24 
= 0.5)  suggesting that the enantioselective chirality of the starting amino acid ester was retained 
and the final product is not a 50/50 racemic mixture. 
 
The synthesis of 2b was done in a different manner to that reported in the original paper.9 
Originally 1-bromo-4-(bromomethyl)-2,5-dimethylbenzene as opposed to 8 was synthesised21 but 
a complication was encountered in the synthesis of 2b when coupling with 9 was unsuccessfully 
attempted. It has been suggested that the butyl lithium reagent successfully used in the synthesis 
of 2a deprotonates the adjacent ortho methyl group on the bromo benzene ring. As iodine has been 
reported as being a much more reactive leaving group than bromine in Weinreb amide coupling 
reactions,22 the synthesis of 1-iodo-4-(bromomethyl)-2,5-dimethylbenzene was attempted 
(scheme 2).  Using a reported synthetic strategy as a basis for trying an alternative 
isopropylmagnesium chloride base for the Weinreb amide coupling step (step b in scheme 4) 
proved to be an effective way of forming the bond.22 
 
Some alterations were made to the final stages of the synthesis of 2a and 2b. The final two steps 
(as shown in steps c and d in scheme 4) are reported in the same experimental procedure and no 
column is reportedly used to purify the product.9 These stages were conducted separately and a 
column was used.  
 
Scheme 1. Reagents and conditions: (a) t-BuCHO, Et3N, toluene, 150 °C, Dean Stark, 24 h, 83%; (b) 
CH3CO2Cl, Et3N, toluene, 150 °C, Dean Stark, 24 h, 77%; (c) MeI, LiHDMS, DMPU, THF, hexane, -74 
°C, 4.5 h, 86%; (d) LiCl, KBH4, toluene, THF, 45 °C, 24 h, 80%. 
 
  
Scheme 2. Conditions: Reflux, 24 h, 42%. 
 
 
 
Scheme 3. Conditions: DCM, 0 °C – RT, 24 h, 77%. 
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Scheme 4. Reagents and conditions: (a) 8, NaH, DMF, 24 h, 77%; (b) 9, iPrMgCl, THF, -78 °C – RT, 
3 h, 42%; (c) p-TsOH monohydrate, MeOH, 50 °C, 24 h, 85%; (d) KOH, EtOH, 90 °C, 24 h, 56%. 
 
The synthesis of phosphoramidate compounds was achieved using previously published 
procedures.23,24 A total of six different phosphoramidate benzyl ether derivatives (16 – 21) were 
synthesised. More than two different primary peaks were observed in the 31P NMR spectra for 
compounds 16 – 21 likely due to racemisation of the chiral carbon centre of the benzyl ether 
derivatives under high temperature. The aryl group of the phosphoramidate chosen was simple 
phenol as opposed to naphthol as the lipophilicity of the parent BED analogues is already 
comparatively high. L-alanine was chosen as the amino acid component as all the different ProTide 
prodrugs which have made it to clinical trials have possessed this functionality.11 The three 
different ester components chosen were methyl, benzyl and isopropyl groups (figure 2). A benzyl 
L-alaninyl phosphoramidate moiety is used in Acelarin or NUC-103112 and an isopropyl L-alaninyl 
phosphoramidate moiety is used in the FDA approved Sofosbuvir used to treat hepatitis C.24  
 
 
Figure 2. Structures of the phosphorochloridates synthesised with methyl (15a), benzyl (15b) and 
isopropyl (15c) ester groups. 
 
Scheme 5. Reagents and conditions: (a) Isopropanol, p-TsOH monohydrate, toluene, 120 °C, 24 h, 
88%; (b) Phenyl dichlorophosphate, Et3N, DCM, -78 °C – RT, 2 h, 55%; (c) 15c, tBuMgCl, THF, 24 
h, 15%.  
 
 
 
 
 
 
 
 
 
Table 2. Synthesised phosphoramidate BED analogues. 
 
Compound Ar AA RI RII % Yield 31P NMR  (ppm) 
16 Ph L-Ala CH3 H 44% 2.55, 2.52, 2.47, 2.17 
17 Ph L-Ala Bzl H 65% 3.14, 2.67, 2.26 
18 Ph L-Ala iPr H 50% 3.13, 2.77, 2.41 
19 Ph L-Ala CH3 CH3 99% 3.72, 3.37, 3.30 
20 Ph L-Ala Bzl CH3 87% 3.60, 3.51, 3.08, 3.05 
21 Ph L-Ala iPr CH3 15% 2.58, 2.52, 2.29, 2.27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We performed a series of stability and metabolic assays to assess the ability of the prepared 
ProTides to be appropriately processed to the pharmacologically active monophosphate. As a 
representative example, we are showing results for 16, as all the different analogues reported 
produced very similar results. 
  
Acid and Base Stability 
 
 
16 was subjected to a pH 8 stability experiment in pH 8 buffer over 13 hours.25 No degradation is 
discernable in the NMR spectra confirming that ProTide BED analogue 16 is stable in mildly basic 
conditions. This result is relevant as the lumen has been reported to reach a pH of 7.6.26  
 
 
 
Figure 3. Stacked 31P NMR spectra showing 16 remaining stable and not degrading in the presence 
of pH 8 buffer over 13 hours. 
 
 
An acid stability experiment was conducted involving 16 in pH 1.5 buffer over 13 h.25 There was 
no discernable change over 13 hours at pH 1.5 suggesting that ProTide BED analogues are able to 
withstand the acidic conditions of the stomach.25,26 Other phosphoramidate benzyl ether 
derivative analogues tested follow the same profile of stability in acidic and basic conditions.  
 
 Figure 4. Stacked 31P NMR spectra showing 16 remaining stable and not degrading in the presence 
of pH 1.5 buffer over 13 hours. 
 
 
 
 
 
 
 
 
 
Carboxypeptidase Y Processing 
 
A carboxypeptidase Y processing experiment of 16 was conducted following a previously reported 
experimental procedure.12 Carboxypeptidase Y is used as a model for native enzymes in the human 
body such as Cathepsine A27 which initiates phosphoramidate processing in vivo. Processing was 
slow as the experiment was conducted over two weeks as opposed to the expected timescale of 
minutes or hours. After two weeks the reaction mixture was filtered and subjected to mass 
spectrometric analysis and unexpectedly a mass corresponding to the pharmacologically active 
monophosphate was detected. The complete processing to the monophosphate was unexpected, 
as carboxypeptidase has not been previously reported as being capable of fully processing 
phosphoramidates to the monophosphate. The complete processing to the monophosphate is 
perhaps due to a chemical difference of the benzyl ether derivatives when compared with 
nucleosides. The adjacent amine group may be responsible for the processing from the 
intermediate shown in figure 5 to the monophosphate and may also contribute to the atypical 
processing speed when compared to previously reported phosphoramidates of nucleosides.12 
 
 It was considered that the unusually slow processing rate was perhaps due to the fact that the 
experiment was conducted at ambient temperature as opposed to 37 °C, however, a repetition of 
the experiment conducted at 37 °C gave comparable results. Carboxypeptidase processing 
experiments of phosphoramidate BED analogues at ambient temperature and 37 °C consistently 
resulted in comparable processing speeds suggesting that analogues 16 – 21 are poor substrates 
of carboxypeptidase relative to previously reported phosphoramidates of nucleosides.12  
 
 
 
Figure 5. Stacked 31P NMR spectra showing metabolism of 16 by carboxypeptidase in acetone-d6 
and Trizma buffer to the desired monophosphate over 2 weeks. 
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Stability in Human Serum  
 
 
A stability study of 16 in human serum was also conducted following a previously reported 
procedure.12 The primary product was the therapeutically relevant monophosphate confirmed by 
mass spectrometry by analysing the reaction mixture after 12 h and using 31P NMR (figure 6). The 
estimated half-life for this reaction is around 14 hours and this is the case for all the 
phosphoramidate BED analogues tested. This figure was calculated from the change of the 
integrations of the two peaks over time. An accurate half-life cannot be calculated due to the 
margin of error implicit in determining changes in relative concentrations via changes in the area 
of 31P NMR peaks. The data shown in figure 6 are a qualitative assessment of the capacity of human 
serum to process phosphoramidate BED analogues to the desired pharmacologically active 
monophosphate as opposed to an accurate quantitative measure of the rate of processing. 
 
 
 
Figure 6. Stacked 31P NMR spectra showing metabolism of 16 in human serum to the desired 
monophosphate over 12 hours 
Neuronal Cell Lysate Experiment 
 
Neuronal cell lysate and activator was used to conduct a cell lysate experiment following 
previously described experimental procedures.23,28,29 The main product of the processing of 16 
was the desired monophosphate. Mass spectrometric analysis of the purified reaction mixture 
after 4 days in positive mode gave peaks of m/z 436.20 and m/z 459.30 which correspond to 
monophosphate peaks of [M+H] and [M+Na+] respectively. The estimated half-life for the 
experiment is around 48 hours which is consistent with the data obtained from the other 
phosphoramidate BED analogues tested in neuronal cell lysate. The results of the experiment 
shown in figure 7 are suggestive that phosphoramidate BED analogues can be processed to the 
pharmacologically active monophosphate in neurons. The multiple peaks that can be seen for the 
parent compound are likely due to racemisation of the 2 chiral carbon centres of the benzyl ether 
derivative and L-alanine amino acid of the phosphoramidate.  
 
 
Figure 7. Stacked 31P NMR spectra showing the metabolism of 16 in neuronal cell lysate to the 
desired monophosphate over 4 days. 
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Processing Experiment Approximate Processing Half-Lives 
Carboxypeptidase Y 14 Days 
Neuronal cell lysate 48 Hours 
Human serum 14 Hours 
 
Table 3.  Representative estimated processing rates for all the phosphoramidate BED analogues 
tested in carboxypeptidase Y, neuronal cell lysate and human serum processing experiments.  
 
The synthesis of phosphoramidate analogues of non-nucleoside sphingosine 1-phosphate receptor 
modulators was achieved. Phosphoramidate benzyl ether derivates have been shown to be 
processed to the pharmacologically active monophosphate in a range of metabolic processing 
experiments including neuronal cell lysate and have an acceptable stability profile in acidic and 
basic conditions. The application of ProTide technology to 2b can bypass the poor phosphorylation 
problem reported in the original paper.9 Interestingly these compounds seem to be poor 
substrates of carboxypeptidase, the enzyme generally indicated as responsible for the first step in 
the activation process of ProTides. These data suggest a possible alternative mechanism of 
activation for this class of compounds. The ProTide BED analogues synthesised are promising 
agents and the previously reported biological data9 suggest that the novel compounds reported 
herein are suitable for in vivo testing.  
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Experimental 
 
General 
 
All experiments involving water-sensitive compounds were carried out under anhydrous 
conditions. Dry solvents were purchased from Sigma-Aldrich. 
 
Pre-coated, aluminium backed plates supplied by Merck (60 F254, 0.2 mm thickness) were 
visualised under both short and long wave ultraviolet light (254 nm and 366 nm), or by burning 
using TLC indicators such as vanillin and potassium permanganate solution. 
 
Column chromatography was carried out using silica gel supplied by Fisher (60A, 35-70 Ɋm). Glass 
columns were slurry packed using the appropriate eluent with the sample being loaded pre-
adsorbed onto silica gel. Fractions containing the desired product were identified by TLC, 
combined and the solvent removed in vacuo. 
 1H NMR (500 MHz), 13C NMR (125 MHz), 31P NMR (202 MHz) were recorded on a Bruker Avance 
500 MHz spectrometer at 25 C. Spectra were calibrated to the deuterated solvent used. Chemical 
shifts are detailed in parts per million (ppm) downfield from tetramethylsilane. For 31P NMR 
experiments, chemical shifts are quoted in parts per million relative to an external phosphoric acid 
standard. Coupling constants are described in Hertz (J). The following abbreviations are used in 
the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), b 
(broad), m (multiplet) and dd (doublet of doublets).  
 
Analytical and preparative HPLC were conducted by Varian Prostar (LC Work Station- Varian 
Prostar 335 LC detector, Varian fraction collector (model 701), Prostar 210 solvent delivery 
system, using Agilent Eclipse Plus C18 (5 Ɋm) as an analytical column and a Varian Pursuit XRs 5 
C18 (150 x 21.2 mm) model as a preparative column. The software used was Galaxie 
Chromatography Data System. 
 
Low resolution mass spectrometry was performed on a Bruker Daltonics MicroTOF device 
(electrospray ionisation) in either positive and/or negative mode.  
 
Syntheses 
 
Standard procedure for phosphorochloridate synthesis 
 
To a stirred solution of the appropriate amino acid ester salt (1 eq) and the appropriate aryl 
dichlorophosphate (1 eq) in anhydrous DCM was added dropwise at  -78 C anhydrous Et3N (2 eq). 
Following the addition, the reaction mixture was stirred at -78 C for 30 min and then at room 
temperature for 1 h. Formation of the desired compound was monitored by 31PNMR. After this 
period the solvent was removed under reduced pressure to give an oil. Most of the aryl 
phosphorochloridates synthesised were purified by flash column chromatography (eluting with 
hexane - ethyl acetate 70:30 v/v). 
(2S)-methyl 2-((((R)-2-amino-2-methyl-3-((4-(4-(p-tolyl) butanoyl) benzyl) oxy) propoxy) 
(phenoxy) phosphoryl) amino) propanoate (16) 
 
Compound 16 was prepared from 2a (254 mg, 0.72 mmol), tBuMgCl in THF (1 M, 0.72 ml, 0.72 
mmol) and phosphorochloridate 15a (199 mg, 0.72 mmol) in anhydrous THF (20 ml) under 
anhydrous conditions. The reaction was left to stir for 24 hours. After 24 hours the solvent was 
removed in vacuo and the desired product was isolated using flash chromatography (methanol – 
ethyl acetate 0:100 v/v increasing to 10:90 v/v) giving the desired oil product as a mixture of 2 
diastereoisomers (44%, 0.188 g). The resulting oil was further purified using preparative reverse-
phase HPLC (0.1% TFA in H2O – ACN 20:80 v/v increasing to 100:0 v/v in 35 min) giving the 
desired product (6%, 0.026 g).  
31P NMR (MeOD, 202 MHz):  3.74, 3.37, 3.30. 1H NMR (MeOD, 500 MHz):  7.84 (2H, m, ArH), 7.41 
(2H, m, ArH), 7.27 (2H, t, J = 8.5 Hz, ArH), 7.12 (3H, m, ArH), 6.97 (4H, s, ArH), 4.57 (2H, m, PhCH2O), 
4.09 (2H, m, CH2OP), 3.88 (1H, m, CH3CH), 3.56 (3H, m, OCH3), 3.46 (2H, m, CCH2O), 2.90 (2H, m, 
COCH2), 2.55 (2H, t, J = 7.5 Hz, PhCH2), 2.19 (3H, s, PhCH3), 1.88 (2H, quin, J = 7 Hz, CH2CH2CH2), 
1.24 (3H, m, CHCH3), 1.21 (3H, m, CCH3). 13C NMR (MeOD, 125 MHz):  200.62 (C=O), 175.04 (C=O), 
142.74 (2d, 2JC-P = 3.3 Hz, POC-Ar), 138.57 (C-Ar), 136.51 (C-Ar), 136.0 (C-Ar), 129.52 (CH-Ar), 
128.64 (CH-Ar), 128.02 (CH-Ar), 127.59 (CH-Ar), 127.57 (CH-Ar), 125.08 (CH-Ar), 120.03 (2d, 3JC-
P = 4.9 Hz, CH-Ar), 72.55 (OCH2C), 70.81 (d, 2JC-P = 3.6 Hz, CH2OP), 70.66 (PhCH2O), 51.50 (OCH3), 
50.11 (CHCH3), 41.71 (NH2C), 37.31 (COCH2), 34.30 (PhCH2), 25.94 (CH2CH2CH2), 19.69 (PhCH3), 
19.04 (m, CH3C), 17.14 (CHCH3). MS (ES+) m/z 597.3 (MH+). Reverse-phase analytical HPLC (0.1% 
TFA in H2O – ACN 20:80 v/v increasing to 0:100 v/v in 35 min), 1 ml/min, ɉ = 263 nm showed a 
peak with a tR = 14.84 min (99.1%).   
 
 
 
 
 
 
 
(2S)-benzyl 2-((((R)-2-amino-2-methyl-3-((4-(4-(p-tolyl) butanoyl) benzyl) oxy) propoxy) (phenoxy) 
phosphoryl) amino) propanoate (17) 
 
Compound 17 was prepared from 2a (300 mg, 0.84 mmol), tBuMgCl in THF (1 M, 0.84 ml, 0.84 
mmol) and phosphorochloridate 15b (297 mg, 0.84 mmol) in anhydrous THF (20 ml) under 
anhydrous conditions. The reaction was left to stir for 24 hours. After 24 hours the solvent was 
removed in vacuo and the desired product was isolated using flash chromatography (methanol – 
ethyl acetate 0:100 v/v increasing to 10:90 v/v) giving the desired oil product as a mixture of 2 
diastereoisomers (65%, 0.365 g). The resulting oil was further purified using preparative reverse-
phase HPLC (0.1% TFA in H2O – ACN 20:80 v/v increasing to 100:0 v/v in 35 min) twice giving the 
desired product (3%, 0.015 g). 
 31P NMR (MeOD, 202 MHz):  3.71, 3.31, 3.32. 1H NMR (CDCl3, 500 MHz):  7.78 (2H, m, ArH), 7.30-
6.94 (17H, m, ArH), 5.02 (2H, m, PhCH2O), 4.39 (2H, m, PhCH2O), 3.94 (2H, m, CH2OP), 3.89 (1H, m, 
CHCH3), 3.26 (1H, m, NH), 3.19 (2H, s, CCH2O), 2.83 (2H, t, J = 7 Hz, COCH2), 2.58 (2H, t, J = 7.5 Hz, 
PhCH2), 2.22 (3H, s, PhCH3), 1.95 (2H, quin, J = 7 Hz, CH2CH2CH2), 1.21 (3H, m, CHCH3), 1.02 (3H, 
m, CCH3). 13C NMR (CDCl3, 125 MHz):  199.80 (C=O), 173.42 (C=O), 150.85 (d, 2JC-P = 6.75 Hz, POC-
Ar), 143.42 (C-Ar), 138.61 (C-Ar), 136.34 (C-Ar), 135.81 (C-Ar), 135.39 (C-Ar), 129.69 (CH-Ar), 
129.65 (CH-Ar), 129.12 (CH-Ar), 128.68 (CH-Ar), 128.65 (CH-Ar), 128.52 (CH-Ar), 128.43 (CH-Ar), 
128.27 (CH-Ar), 128.24 (CH-Ar), 128.21 (CH-Ar), 128.05 (CH-Ar), 127.98 (CH-Ar), 127.29 (CH-Ar), 
126.02 (CH-Ar), 124.93 (CH-Ar), 122.93 (CH-Ar), 120.81 (CH-Ar), 120.33 (CH-Ar), 74.77 (OCH2C), 
72.73 (d, 2JC-P = 6.88 Hz, CH2OP), 71.40 (PhCH2O), 67.18 (PhCH2O), 60.43 (NH2C), 50.33 (CHCH3), 
37.76 (COCH2), 34.79 (PhCH2), 25.85 (CH2CH2CH2), 21.05 (PhCH3), 20.85 (CH3C), 14.26 (CHCH3). 
MS (ES+) m/z 673.3 (MH+) and 695.3 (MNa+). Reverse-phase analytical HPLC (0.1% TFA in H2O – 
ACN 20:80 v/v increasing to 0:100 v/v in 35 min), 1 ml/min, λ = 263 nm showed a peak with a tR 
= 17.67 min (99.2%).  
 
 
 
 
(2S)-isopropyl 2-((((R)-2-amino-2-methyl-3-((4-(4-(p-tolyl) butanoyl) benzyl) oxy) 
propoxy)(phenoxy) phosphoryl) amino) propanoate (18) 
 
Compound 18 was prepared from 2a (265 mg, 0.75 mmol), tBuMgCl in THF (1 M, 0.75 ml, 0.75 
mmol) and phosphorochloridate 15c (229 mg, 0.75 mmol) in anhydrous THF (20 ml) under 
anhydrous conditions. The reaction was left to stir for 24 hours. After 24 hours the solvent was 
removed in vacuo and the desired product was isolated using flash chromatography (methanol – 
ethyl acetate 0:100 v/v increasing to 10:90 v/v) giving the desired oil product as a mixture of 2 
diastereoisomers (50%, 0.234 g). The resulting oil was further purified using preparative reverse-
phase HPLC (0.1% TFA in H2O – ACN 20:80 v/v increasing to 100:0 v/v in 35 min) giving the 
desired product (14%, 0.065 g). 
31P NMR (MeOD, 202 MHz):  3.79, 3.49, 3.41. 1H NMR (MeOD, 500 MHz):  7.83 (2H, m, ArH), 7.39 
(2H, m, ArH), 7.26 (2H, m, ArH), 7.12 (3H, m, ArH), 6.97 (4H, s, ArH), 4.91 (1H, m, CH(CH3)2), 4.56 
(2H, m, PhCH2O), 4.11 (2H, m, CH2OP), 3.81 (1H, m, CHCH3), 3.50 (2H, m, CCH2O), 2.89 (2H, m, 
COCH2), 2.54 (2H, t, J = 7.5 Hz, PhCH2), 2.18 (3H, s, PhCH3), 2.05 (1H, s, NH), 1.88 (2H, quin, J = 7.5 
Hz, CH2CH2CH2), 1.25 (3H, m, CHCH3), 1.19 (3H, m, CCH3), 1.11 (3H, m, CHCH3), 1.10 (3H, m, 
CHCH3). 13C NMR (MeOD, 125 MHz):  200.62 (C=O), 172.99 (C=O), 142.73 (2d, 2JC-P = 2 Hz, POC-
Ar), 138.56 (C-Ar), 136.47 (C-Ar), 135.06 (C-Ar), 129.52 (CH-Ar), 128.65 (CH-Ar), 128.03 (CH-Ar), 
127.58 (CH-Ar), 127.55 (CH-Ar), 125.08 (CH-Ar), 125.04 (CH-Ar), 120.04 (2d, 3JC-P = 4.75 Hz, CH-
Ar), 72.54 (OCH2C), 70.77 (PhCH2O), 70.61 (d, 2JC-P = 1.63 Hz, CH2OP), 68.98 (OCH(CH3)2), 56.21 
(NH2C), 50.54 (CHCH3), 37.31 (COCH2), 34.30 (PhCH2), 25.94 (CH2CH2CH2), 20.60 (OCHCH3), 20.52 
(OCHCH3), 19.72 (PhCH3), 19.14 (m, CH3C), 17.11 (CHCH3). MS (ES+) m/z 625.3 (MH+) and 647.3 
(MNa+). Reverse-phase analytical HPLC (0.1% TFA in H2O – ACN 20:80 v/v increasing to 0:100 v/v 
in 35 min), 1 ml/min, λ = 263 nm showed a peak with a tR = 17.30 min (95.5%).  
 
 
 
 
 
(2S)-methyl 2-((((R)-2-amino-3-((2,5-dimethyl-4-(4-(p-tolyl) butanoyl) benzyl) oxy)-2-
methylpropoxy) (phenoxy) phosphoryl) amino) propanoate (19) 
 
Compound 19 was prepared from 2b (500 mg, 1.3 mmol), tBuMgCl in THF (1 M, 1.3 ml, 1.3 mmol) 
and phosphorochloridate 15a (360 mg, 1.3 mmol) in anhydrous THF (20 ml) under anhydrous 
conditions. The reaction was left to stir for 24 hours. After 24 hours the solvent was removed in 
vacuo and the desired product was isolated using flash chromatography (methanol – ethyl acetate 
0:100 v/v increasing to 10:90 v/v) giving the desired oil product as a mixture of 2 diastereoisomers 
(99%, 0.803 g). The resulting oil was further purified using preparative reverse-phase HPLC (0.1% 
TFA in H2O – ACN 20:80 v/v increasing to 100:0 v/v in 35 min) twice giving the desired product 
(11%, 0.087 g). 
31P NMR (MeOD, 202 MHz):  3.73, 3.43, 3.31. 1H NMR (MeOD, 500 MHz):  7.44 (1H, m, ArH), 7.38 
(2H, t, J = 8 Hz, ArH), 7.27 (4H, m, ArH), 7.07 (4H, m, ArH), 4.63 (2H, m, PhCH2O), 4.25 (2H, m, 
CH2OP), 3.99 (1H, m, CH3CH), 3.68 (3H, m, OCH3), 3.60 (2H, m, CCH2O), 3.33 (1H, m, NH), 2.90 (2H, 
m, COCH2), 2.63 (2H, t, J = 7.5 Hz, PhCH2), 2.40 (3H, m, PhCH3), 2.35 (3H, m, PhCH3), 2.30 (3H, s, 
PhCH3), 1.96 (2H, quin, J = 7 Hz, CH2CH2CH2), 1.40 (3H, m, CHCH3), 1.35 (3H, m, CCH3). 13C NMR 
(MeOD, 125 MHz):  205.25 (C=O), 173.89 (C=O), 150.50 (2d, 2JC-P = 4.88 Hz, POC-Ar), 138.51 (C-
Ar), 138.31 (C-Ar), 137.71 (C-Ar), 135.08 (C-Ar), 134.81 (C-Ar), 134.19 (C-Ar), 131.92 (CH-Ar), 
130.07 (CH-Ar), 129.52 (CH-Ar), 128.66 (CH-Ar), 128.05 (CH-Ar), 125.08 (CH-Ar), 120.07 (2d, 3JC-P 
= 4.75 Hz, CH-Ar), 71.17 (OCH2C), 70.72 (d, 2JC-P = 2.6 Hz, CH2OP), 70.57 (PhCH2O), 56.18 (NH2C), 
51.50 (OCH3), 50.34 (CHCH3), 40.31 (COCH2), 34.25 (PhCH2), 26.00 (CH2CH2CH2), 19.73 (PhCH3), 
19.44 (PhCH3), 19.06 (PhCH3), 18.87 (CH3C), 17.12 (CHCH3). MS (ES+) m/z 625.3 (MH+) and 647.3 
(MNa+). Reverse-phase analytical HPLC (0.1% TFA in H2O – ACN 20:80 v/v increasing to 0:100 v/v 
in 35 min), 1 ml/min, λ = 245 nm showed a peak with a tR = 17.03 min (94.6%).  
 
 
 
 
 
(2S)-benzyl 2-((((R)-2-amino-3-((2,5-dimethyl-4-(4-(p-tolyl) butanoyl) benzyl) oxy)-2-
methylpropoxy) (phenoxy) phosphoryl) amino) propanoate (20) 
 
Compound 20 was prepared from 2b (500 mg, 1.3 mmol), tBuMgCl in THF (1 M, 1.3 ml, 1.3 mmol) 
and phosphorochloridate 15b (459 mg, 1.3 mmol) in anhydrous THF (20 ml) under anhydrous 
conditions. The reaction was left to stir for 24 hours. After 24 hours the solvent was removed in 
vacuo and the desired product was isolated using flash chromatography (methanol – ethyl acetate 
0:100 v/v increasing to 10:90 v/v) giving the desired oil product as a mixture of 2 diastereoisomers 
(87%, 0.791 g). The resulting oil was further purified using preparative reverse-phase HPLC (0.1% 
TFA in H2O – ACN 20:80 v/v increasing to 100:0 v/v in 35 min) giving the desired product (8%, 
0.07 g). 
31P NMR (MeOD, 202 MHz):  3.73, 3.37, 3.29. 1H NMR (MeOD, 500 MHz):  7.42 (1H, m, ArH), 7.33 
(7H, m, ArH), 7.23 (4H, m, ArH), 7.07 (1H, m, ArH), 5.11 (2H, m, PhCH2O), 4.61 (2H, m, PhCH2O), 
4.22 (2H, m, CH2OP), 4.04 (1H, m, CHCH3), 3.60 (2H, m, CCH2O), 3.37 (1H, m, NH), 2.88 (2H, t, J = 7 
Hz, COCH2), 2.63 (2H, t, J = 7.5 Hz, PhCH2), 2.40 (3H, s, PhCH3), 2.34 (3H, s, PhCH3), 2.30 (3H, s, 
PhCH3), 2.04 (2H, s, NH2), 1.95 (2H, quin, J = 7.5 Hz, CH2CH2CH2), 1.34 (3H, m, CHCH3), 1.33 (3H, m, 
CCH3). 13C NMR (MeOD, 125 MHz):  207.18 (C=O), 175.67 (C=O), 152.48 (d, 2JC-P = 6.5 Hz, POC-Ar), 
140.50 (C-Ar), 140.28 (C-Ar), 139.69 (C-Ar), 137.76 (C-Ar), 137.07 (C-Ar), 137.81 (C-Ar), 136.16 
(C-Ar), 133.89 (CH-Ar), 133.84 (CH-Ar), 132.07 (CH-Ar), 131.50 (CH-Ar), 130.66 (CH-Ar), 130.25 
(CH-Ar), 130.04 (CH-Ar), 130.03 (CH-Ar), 129.94 (CH-Ar), 129.86 (CH-Ar), 129.84 (CH-Ar), 127.08 
(CH-Ar), 127.03 (CH-Ar), 122.11 (2d, 3JC-P = 4.63 Hz, CH-Ar), 73.17 (OCH2C), 72.70 (PhCH2O), 69.50 
(d, 2JC-P = 5.38 Hz, CH2OP), 68.68 (PhCH2O), 58.23 (NH2C), 50.50 (CHCH3), 42.29 (COCH2), 36.24 
(PhCH2), 27.98 (CH2CH2CH2), 21.73 (PhCH3), 21.45 (PhCH3), 21.05 (PhCH3), 20.85 (CH3C), 19.13 
(CHCH3). MS (ES+) m/z 701.5 (MH+) and 723.4 (MNa+). Reverse-phase analytical HPLC (0.1% TFA 
in H2O – ACN 20:80 v/v increasing to 0:100 v/v in 35 min), 1 ml/min, λ = 245 nm showed a peak 
with a tR = 19.88 min (97.3%).  
 
 
 
(2S)-isopropyl 2-((((R)-2-amino-3-((2,5-dimethyl-4-(4-(p-tolyl) butanoyl) benzyl) oxy)-2-
methylpropoxy) (phenoxy) phosphoryl) amino) propanoate (21) 
 
Compound 21 was prepared from 2b (499 mg, 1.3 mmol), tBuMgCl in THF (1 M, 1.3 ml, 1.3 mmol) 
and phosphorochloridate 15c (397 mg, 1.3 mmol) in anhydrous THF (20 ml) under anhydrous 
conditions. The reaction was left to stir for 24 hours. After 24 hours the solvent was removed in 
vacuo and the desired product was isolated using flash chromatography (methanol – 
dichloromethane 0:100 v/v increasing to 10:90 v/v) giving the desired oil product as a mixture of 
2 diastereoisomers (15%, 0.129 g). The resulting oil was further purified using preparative 
reverse-phase HPLC (0.1% TFA in H2O – ACN 20:80 v/v increasing to 100:0 v/v in 35 min) giving 
the desired product (8%, 0.065 g). 
31P NMR (MeOD, 202 MHz):  3.78, 3.51, 3.43. 1H NMR (MeOD, 500 MHz):  7.31 (1H, d, J = 3.5 Hz, 
ArH), 7.26 (2H, m, ArH), 7.15 (1H, m, ArH), 7.12 (3H, m, ArH), 6.96 (4H, s, ArH), 4.85 (1H, m, 
CH(CH3)2),  4.51 (2H, m, PhCH2O), 4.13 (2H, m, CH2OP), 3.80 (1H, m, CHCH3), 3.51 (1H, m, CCH2O), 
3.47 (1H, m, CCH2O), 2.78 (2H, t, J = 7.5 Hz, COCH2), 2.51 (2H, t, J = 7.5 Hz, PhCH2), 2.28 (3H, s, 
PhCH3), 2.23 (3H, s, PhCH3), 2.18 (3H, s, PhCH3), 1.84 (2H, quin, J = 7.5 Hz, CH2CH2CH2), 1.18 (6H, 
m, CHCH3), 1.12 (3H, m, CCH3), 1.11 (3H, m, CHCH3). 13C NMR (MeOD, 125 MHz):  205.24 (C=O), 
173.54 (C=O), 150.53 (2d, 2JC-P = 2 Hz, POC-Ar), 138.51 (C-Ar), 138.32 (C-Ar), 137.70 (C-Ar), 135.08 
(C-Ar), 138.56 (C-Ar), 134.80 (C-Ar), 134.17 (C-Ar), 131.88 (CH-Ar), 130.07 (CH-Ar), 129.52 (CH-
Ar), 128.66 (CH-Ar), 128.05 (CH-Ar), 125.09 (CH-Ar), 120.14 (2d, 3JC-P = 4.75 Hz, CH-Ar), 71.18 
(OCH2C), 70.74 (PhCH2O), 68.98 (OCH(CH3)2), 67.59 (2d, 2JC-P = 5.13 Hz, CH2OP), 56.22 (NH2C), 
50.52 (CHCH3), 40.31 (COCH2), 34.25 (PhCH2), 26.00 (CH2CH2CH2), 20.58 (OCHCH3), 20.53 
(OCHCH3), 19.73 (PhCH3), 19.44 (PhCH3), 18.92 (PhCH3), 18.84 (CH3C), 17.13 (CHCH3). MS (ES+) 
m/z 653.3 (MH+) and 675.3 (MNa+). Reverse-phase analytical HPLC (0.1% TFA in H2O – ACN 20:80 
v/v increasing to 0:100 v/v in 35 min), 1 ml/min, λ = 245 nm showed a peak with a tR = 18.64 min 
(98.2%).  
 
 
 
 
Assays 
 
Cell lysate assay 
 
The experiment was carried out by dissolving phosphoramidate test compound (5 mg) in acetone-
d6 (0.3 ml) and adding 0.1 ml of Trizma buffer (pH 7.6). After the 31P NMR data were recorded at 
25 C as a control, 0.125 ml cell lysate and 0.02 ml activator was added to the sample. Next, the 
sample was shaken and submitted to 31P NMR experiments at 37 C and the spectra were recorded 
every 7 min over 13 h. 31P NMR recorded data were processed and analysed with the Bruker 
Topspin 2.1 program. One experiment was performed for each compound tested. 
 
Human serum assay 
 
The experiment was carried out by dissolving test compound in DMSO (0.05 ml) and D2O  (0.15 
ml). After the 31P NMR data were recorded at 37 C as a control, a previously defrosted human 
serum (male AB plasma) (0.3 ml) was added to the sample. Next, the sample was submitted to 31P 
NMR experiments at 37 C and the spectra were recorded every 15 min over 13 h. 31P NMR 
recorded data were processed and analysed with the Bruker Topspin 2.1 program. One experiment 
was performed for each compound tested. 
 
Carboxypeptidase Y assay 
 
The experiment was carried out by dissolving phosphoramidate compound (3 mg) in acetone-d6 
(0.15 ml) and adding 0.3 ml of Trizma buffer (pH 7.6). After the 31P NMR data were recorded at 25 C as a control, a previously defrosted carboxypeptidase Y (0.1 mg dissolved in 0.15 ml of Trizma) 
was added to the sample. Next, the sample was submitted to 31P NMR experiments the spectra 
were recorded every day over 2 weeks. 31P NMR recorded data were processed and analysed with 
the Bruker Topspin 2.1 program.1 Two experiments were performed for each compound tested. 
Acid stability 
 The stability assay toward hydrolysis by aqueous buffer at pH 1.5 was conducted using in situ 31P 
NMR (202 MHz). The experiment was carried out by dissolving test compound (3 mg) in methanol-
d4 (0.1 ml) and then adding buffer of pH 1.5 (prepared from HCl and KCl). Next, the sample was 
subjected to 31P NMR experiments at 25 C and the spectra were recorded every 12 min over 13 h. 
 
Base stability 
 
The stability assay toward hydrolysis by aqueous buffer at pH 8 was conducted using in situ 31P 
NMR (202 MHz). The experiment was carried out by dissolving test compound (3 mg) in methanol-
d4 (0.1 ml) and then adding pH 8 buffer (prepared from tris(hydroxymethyl)aminomethane and 
HCl). Next, the sample was subjected to 31P NMR experiments at 25 C and the spectra were 
recorded every 12 min over 13 h. 
 
Generating cell lysate 
 
J1 ES cell-derived neurons were generated in vitro as previously described.28 The glutamatergic-
like neurons were cultured at a density of 5.4E+5 cells/cm2 for 2 weeks before the lysis of the 
neurons. 6 million neurons were lysed in 300 Ɋl of lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 % Triton, 0.2 % Sodiumdeoxycholate, 10 % Glycerol). Cell lysate was 
centrifuged at 3000 rpm for 10 min and transferred into a fresh tube. It was stored at –20 °C until 
further use. To improve enzyme performance MgCl2 and ATP was added in form of a DNA ligation 
buffer (T4 DNA Ligase Buffer, NEB).    
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